Through its Germany-based subsidiary Berlin-Chemie Menarini, Italian drugmaker Menarini has entered into a global license agreement for PA799, a class I PI3K inhibitor.
PA799 was originated by Chugai (TYO: 4519), which is majority owned by Swiss pharma giant Roche (ROG: SIX), which conducted a Phase I study for solid tumors in Europe. With its high selectivity for class I enzyme, the drug candidate showed a good safety profile in the clinical trial.
Terms of the deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze